0
Following
1
Follower
0
Boost

Chronic Cutaneous Ulcer Market by DelveInsight

Chronic Cutaneous Ulcers are wounds that do not heal through an orderly and timely reparation, which in turn, hinders the production of anatomic and functional integrity. This can also be re-defined as “interruption on the continuity of the body's tissue that requires a prolonged time to heal, does not heal, or recurs.” DelveInsight's "Chronic Cutaneous Ulcer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Chronic Cutaneous Ulcer, historical and forecasted epidemiology as well as the Chronic Cutaneous Ulcer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Chronic Ulcers are mainly caused by conditions that slow or stop the healing process, such as inadequate blood supply or low oxygen, an infection, weak immune system, swelling in the tissues around the wound. These are mainly classified as vascular ulcers (e.g., venous and arterial ulcers), diabetic ulcers, and pressure ulcers. Some facts of Chronic Cutaneous Ulcer Market Report are: · As per the study conducted by Nussbaum at al. (2018), a rough prevalence rate for chronic nonhealing wounds in developed countries is 1−2% of the general population. · Tripathi et al. (2019), conducted a study which stated that, estimated 1-2% of adults in developed countries will have a CCU during their lifetime, which may lead to complications such as infection, resulting in a cycle that contributes to poor outcomes.
Health
healthcare
+ 1 interests

X-linked hypophosphatemia Market by DelveInsight

X-linked hypophosphatemia is a hereditary renal phosphate-wasting disorder characterized by hypophosphatemia, rickets and/or osteomalacia, and diminished growth. Phosphate levels are low because phosphate is abnormally processed in the kidneys, which causes a loss of phosphate in the urine (phosphate wasting) and leads to soft, weak bones (rickets). XLH is usually diagnosed in childhood. Features include bowed or bent legs, short stature, bone pain, and severe dental pain. XLH is the most common form of hereditary hypophosphatemic rickets. DelveInsight's "X Linked Hypophosphatemia Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the X Linked Hypophosphatemia, historical and forecasted epidemiology as well as the X Linked Hypophosphatemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Some facts of X Linked Hypophosphatemia Market Report are: · According to study conducted by He ́le`ne et al., titled “Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms”, the estimated prevalence of X-linked hypophosphatemia was 4.8 per 100,000. · As per Endocrine Society, the Food and Drug Administration (FDA) estimates that XLH affects about 3,000 children and 12,000 adults in the United States · According to Phosphodiabetes E.V. Netzwerk Information Austausch, estimates that X-linked hypophosphatemia (XLH) is the most common form of vitamin D-resistant rickets and, with a prevalence of 4.8 cases per 100,000 individuals, is considered a rare disease.
Health
healthcare
+ 1 interests

Necrotizing Enterocolitis Market by DelveInsight

Necrotizing Enterocolitis (NEC) is an inflammatory disease of intestine largely occurring in preterm infants with a wide range of damage from minimal injury limited to mucosa to extensive necrosis of bowel wall and perforation. It is the most common neonatal gastrointestinal emergency, particularly in those born at, 32 weeks’ gestation and/or, 1,500 g birth weight. The exact cause of NEC isn’t known. However, it’s believed that a lack of oxygen during a difficult delivery may be a contributing factor. When there’s reduced oxygen or blood flow to the intestine, it can become weak. A weakened state makes it easier for bacteria from the food entering the intestine to cause damage to the intestinal tissues. This can lead to the development of an infection or NEC. DelveInsight's "Necrotizing Enterocolitis Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Necrotizing Enterocolitis, historical and forecasted epidemiology as well as the Necrotizing Enterocolitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Some facts of Necrotizing Enterocolitis Market Report are: · As per Robert C. Holman et al, NEC occurs in approximately 10% of VLBW infants and is associated with 1.0–7.5% of all neonatal intensive care unit admissions. Also, found that approximately 4500 neonates (or approximately 1 infant per 1000 live births) are hospitalized each year in the United States · According to Simon Eaton UK NEC study, estimates based on over 100,000 infants, of whom more than 500 had severe NEC, with an incidence of around 3% in infants <32 weeks gestational age · According to Clare M. Rees et Al, Bell's stage I was the most frequent maximum stage of NEC diagnosed with 45%, stage II at 18% to 24% and stage III at 30% to 37% in the United Kingdom
Health
healthcare
+ 1 interests

Nonalcoholic Steatohepatitis (NASH) Market: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight

Nonalcoholic Steatohepatitis (NASH) is the progressive form of liver injury that carries a risk of progressive fibrosis, cirrhosis, and end-stage liver disease. It is an advanced form of nonalcoholic fatty liver disease (NAFLD), caused by the buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis. NASH usually comes under the category of silent diseases that has very few or no symptoms typically because it does not cause any symptoms until it is too late. In the early period, patients did not complain about anything specific. Even with the advancing fibrosis, the disease may not have any specific problems. However, in the later stages, patients may start developing some non-specific symptoms. DelveInsight's "Nonalcoholic Steatohepatitis (NASH) Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Nonalcoholic Steatohepatitis (NASH), historical and forecasted epidemiology as well as the Nonalcoholic Steatohepatitis (NASH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Some facts of Nonalcoholic Steatohepatitis (NASH) Market are: · Of all the prevalent cases of NAFLD in the 7MM, approximately 19% of the population fulfilled the criteria for NASH. These cases are expected to increase throughout the study period [2018–2030]. · We estimate the highest prevalence of NASH in the United States, accounting close to 50% of the total prevalent cases, followed by Japan. · On the other hand, it is assessed that among the European countries, Germany accounted for the highest prevalent population, followed by Italy. Among all the 7MM countries, Spain had the lowest prevalent population.
Health
healthcare
+ 1 interests

Adrenal Cortex Neoplasms Market: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight

DelveInsight's Adrenal Cortex Neoplasms Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Adrenal Cortex Neoplasms, historical and forecasted epidemiology as well as the Adrenal Cortex Neoplasms market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Adrenal Cortex Neoplasms is rare cancer that originates in the outer layer of the adrenal gland. ACC is also called cancer of the adrenal cortex. A tumor of the adrenal cortex may be functioning (produces surplus hormones than usual) or nonfunctioning (does not produce surplus hormones than usual). Most adrenocortical tumors are functioning. Some facts of Adrenal Cortex Neoplasms Market are: · Adrenal Cortex Neoplasms is a rare malignancy with poor prognosis. It occurs at any age, with two peak incidence: the first in the first decade and the second between 40‒50 years. · In the retrospective review conducted by Wang et al. titled “Prognostic Factors of Adrenal Cortex Neoplasms: An Analysis of the Surveillance Epidemiology and End Results (SEER) Database,” the study population of Adrenal Cortex Neoplasms consist of 60.6% females and 39.4% males. Most of the patients were in stage II (44.6%) followed by stage IV (28.1%), and stage III (21.8%). Only 5.5% of patients were found to be in stage I of the Adrenal Cortex Neoplasms. · According to the retrospective review conducted by Aspinall et al. titled “How is Adrenocortical Cancer being Managed in the UK?,” the incidence of Adrenal Cortex Neoplasms is 0.5‒2 per million per year.
Health
News
+ 1 interests